Effect of Auranofin and Sodium Aurothiomalate on lnterleukin-1 Production from Human Monocytes In Vitro

References

• Blodgett R C, Jr., Heuer M A, Pietrusko R G. Auranofin: A unique oral chrysotherapeutic agent. Semin Arthritis Rheum 1984; 13: 255–73
   PubMed Web of Science ®Google Scholar
• Lorber A, Jackson W H, Simon T M. Effects of chrysotherapy on cell mediated immune response. J Rheumatol 1982; 9(suppl. 8)37–45
   Google Scholar
• Salmeron G, Lipsky P E. Modulation of human immune responsiveness in vitro by Auranofin. J Rheumatol 1982; 9(suppl. 8)25–31
   PubMedGoogle Scholar
• Poubelle P, Damon M, Blotman F, Dayer J-M. Production of mononuclear cell factor by mononuclear phagocytes from rheumatoid synovial fluid. J Rheumatol 1985; 12: 412–17
   PubMedGoogle Scholar
• Wood D D, Ihrie E J, Hamerman D. Release of interleukin-1 from human synovial tissue in vitro. Arthritis & Rheumatism 1985; 28: 853–62
   PubMed Web of Science ®Google Scholar
• Wood D D, Ihrie E J, Dinarello C A, Cohen P L. Isolation of an interleukin-1 like factor from human joint effusions. Arthritis & Rheumatism 1983; 26: 975–83
   PubMed Web of Science ®Google Scholar
• Nouri A ME, Panayi G S, Goodman S M. Cytokines and the chronic inflammation of rheumatic disease. I. The presence of interleukin-1 in synovial fluids. Clin Exp Immunol 1984; 55: 295–302
   PubMedGoogle Scholar
• Dinarello C A. Interleukin-1 and the pathogenesis of the acute-phase response. N.E.J.M. 1984; 311: 1413–18
   PubMed Web of Science ®Google Scholar
• Baek L. New, sensitive rocket immunoelectrophoretic assay for measurement of the reaction between endotoxin and Limulus amoebocyte lysate. J Clin Microbiol 1983; 17: 1013–20
   PubMed Web of Science ®Google Scholar
• Enk C, Remvig L, Bendtzen K. A standardized human T-lymphocyte proliferation assay for detecting soluble accessory factors from monocytes. I. Monocyte and monokine requirements. Acta Path Microbiol Immunol Scand, Sect C, 1984; 92: 93–100
   PubMedGoogle Scholar
• Remvig L, Enk C, Svenson M. A standardized human T-lymphocyte proliferation assay for detecting soluble accessory factors from monocytes. II. Interleukin-1 production and detection. Acta Path Microbiol Immunol Scand, Sect C, 1985; 93: 91
   PubMedGoogle Scholar
• Pedersen S M, Graabaek P M. A unified method for the determination of gold in biological fluids by flameless atomic absorption spectroscopy. Scand J Clin Invest 1977; 37: 91–94
   PubMedGoogle Scholar
• Enk C, Gerstoft J, Moeller S, Remvig L. Interleukin-1 activity in the acquired immunodeficiency syndrome. Scand J Immunol 1986; 23: 491–97
   PubMed Web of Science ®Google Scholar
• Scheinberg M A, Santos L MB, Finkelstein A E. The effect of Auranofin and sodium aurothioma-late on peripheral blood monocytes. J Rheumatol 1982; 9: 366–69
   PubMed Web of Science ®Google Scholar
• Davis P, Johnston C. Effects of gold compounds on function of phagocytic cells. Comparative inhibition of activated polymorphonuclear leukocytes and monocytes from rheumatoid arthritis and control subjects. Inflammation 1986; 10: 311–20
   PubMedGoogle Scholar
• Finkelstein A E, Roisman F R, Walz D T. Effect of auranofin, a new antiarthritic agent, on immune complex-induced release of lysosomal enzymes from human leukocytes. Inflammation 1977; 2: 143–50
   PubMedGoogle Scholar
• Harth M, McCain G A, Orange J F. The effects of auranofin and gold sodium aurothiomalate on the chemiluminescent response of stimulated synovial tissue cells from patients with rheumatoid arthritis. J Rheumatol 1985; 12: 881–84
   PubMedGoogle Scholar
• Barrett M L, Lewis G P. Unique properties of auranofin as a potential anti-rheumatic drug. Agent and Actions 1986; 19: 109–15
   PubMedGoogle Scholar
• Parente J E, Wong K, Davis P, Burka J F, Percy J S. Effects of gold compounds on leukotriene B4, leukotriene C4 and prostaglandin E2 production by polymorphonuclear leukocytes. J Rheumatol 1986; 13: 47–51
   PubMedGoogle Scholar
• Lipsky P E, Ziff M. Inhibition of mitogen-induced human lymphocyte proliferation by gold compounds. J Clin Invest 1977; 59: 455–66
   PubMed Web of Science ®Google Scholar
• Petersen J, Bendtzen K. Immunosuppressive actions of gold salts. Scand J Rheum suppl 1983; 51: 28–35
   PubMedGoogle Scholar
• Remvig L, Svenson M, Enk C. Phorbol myristate acetate – fate and usability in a human interleukin-1 assay. Allergy 1985; 40: 605–11
   PubMedGoogle Scholar
• Crooke S T, Snyder R M. The cellular and molecular pharmacology of auranofin and related gold complexes. Scand J Rheumatol suppl 1986; 63: 1–18
   PubMedGoogle Scholar
• Dahl S L, Coleman M L, Williams H J, et al. Lack of correlation between blood gold concentrations and clinical response in patients with definite or classical rheumatoid arthritis receiving auranofin or gold sodium thiomalate. Arthritis & Rheumatism 1985; 28: 1211–18
   PubMed Web of Science ®Google Scholar
• Griswold D E, Lee J C, Poste G, Hanna N. Modulation of macrophage-lymphocyte interactions by the anti-arthritic compound, auranofin. J Rheumatol 1985; 12: 490–97
   PubMedGoogle Scholar